← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일

현재 선택: 1개 · 임상 갱신 필요 1개

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

API CSV27행 · 1개 프로그램
OverviewMoAPK/PDToxicologyClinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
AntibodyLimited DatastalePhase 2
ATG (rabbit anti-thymocyte globulin, rabbit anti-thymocyte globulin (ATG))
Sumitomo Pharma Switzerland GmbH·Chronic Myeloproliferative Disorde…
183 trials
Overview
Program
rabbit anti-thymocyte globulin (ATG)
Overview
Company
Sumitomo Pharma Switzerland GmbH
Overview
Modality
ANTIBODY
Overview
Target
Chronic Myeloproliferative Disorders
Overview
Indication
Chronic Myeloproliferative Disorders; Leukemia
Overview
Phase
PHASE_2
Overview
Status
ACTIVE
Overview
Content status
Limited Data
Overview
Data Confidence
Data Confidence · Low
Overview
Development Signal
Development Signal · Emerging
Overview
Approval status
Investigational
MoA
Mechanism
targeting RCC-associated minor histocompatibility antigen
MoA
Biomarker
biomarkers
PK/PD
Species
Rabbit
PK/PD
Animal (cat.)
In vitro
PK/PD
Experiment
pharmacokinetic
Toxicology
Species
Rabbit
Toxicology
Animal (cat.)
In vitro
Toxicology
Major finding
hepatotoxicity and recognizing possible biomarkers for environmental monitoring and ecotoxi
Toxicology
CRS
Reported
Clinical
Safety signal
hepatotoxicity and recognizing possible biomarkers for environmental monitoring and ecotoxi
Clinical
Reported PFS
54
Clinical
Reported OS
53
Clinical
Result source
ClinicalTrials.gov NCT00603954
Clinical
Program phase
PHASE_2
Clinical
Trial activity
No active/completed counts
Clinical
Trial ref
NCT00603954